Experimental CAR T-Cell therapy takes on Hard-to-Treat prostate cancer

NCT ID NCT07344311

Recruiting now Disease control Sponsor: Shanghai AbelZeta Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called A-CAR032 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and then infusing them back. The main goals are to check safety and find the right dose, with only 27 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A-CAR032 (a type of CAR T-cell therapy that targets STEAP2 and is armored to resist TGF-beta)
What this could lead to: If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 27 participants, so it is primarily testing safety and dosing. The therapy may not shrink tumors or improve survival, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Beijing GoBroad Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 102200, China
The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, 221006, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310013, China
Tongji Hospital, Tongji Medical College of HUST
RECRUITING

Wuhan, Hubei, 430100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.